Accera’s Ketasyn™ performed favorably in its Phase II age-associated memory impairment study. A low incidence of adverse events along with statistical significance was achieved for Ketasyn™ as it helped to suppress a loss in memory associated with aging.
The Accera pipeline includes therapeutic treatments for Parkinson's, Alzheimer's and other age-related memory loss disorders. The products are in advanced clinical development where they have demonstrated significant efficacy and outstanding safety compared to approved drugs in the marketplace. Accera’s strategy is to advance these products through Phase II testing and, at the appropriate point of high added-value, establish strategic alliances and partnerships to support commercialization. Internal discovery efforts and in-licensing of clinical compounds with novel mechanisms-of-action will expand the pipeline.
Congratulations to President & CEO Steve Orndorff, Ph.D. and the entire Accera team on the great results and continued success!
If you enjoyed this post, get free updates by email or RSS (here).